Japan's Medical Distributors Q1 FY2027: Sales rise, profits fall; Ship leads
Companies compared · 2
Medipal
7459
Ship Healthcare
3360
Takeaway
Sales grew, but core operating profit declined at both companies.
Japan's medical distributors Medipal and Ship Healthcare both grew sales in Q1 FY2027, but operating profit fell at both. Ship led in sales growth and margin, while Medipal's 42.3% net profit jump included securities-sale gains.
Industry overview
In this two-company comparison, sales growth outpaced profit growth. Both companies posted higher revenue alongside lower operating profit.
- Medipal reported sales of ¥989.5 billion, up 4.7% year on year. Ship Healthcare posted ¥176.4 billion, up 8.0%. Growth at Ship Healthcare was supported by expanded SPD services and M&A.
- Operating profit fell 4.7% to ¥13.4 billion at Medipal and 5.7% to ¥2.8 billion at Ship Healthcare. Lower gross profit margins and a lull in equipment demand made it harder to turn higher sales into profit.
- Ship Healthcare had an operating margin of 1.6%, compared with 1.4% at Medipal. The two-company average was 1.5%, highlighting how small differences in profitability can affect results in this low-margin business.
- Net profit rose 42.3% to ¥13.6 billion at Medipal and 2.9% to ¥2.1 billion at Ship Healthcare. Medipal's result was boosted by gains from securities sales, which should be distinguished from growth in its core business.
Sales ranking
Medipal led by a wide margin in sales scale, but Ship Healthcare recorded the faster year-on-year growth. The gap shows that scale and growth momentum are distinct, reflecting different approaches to business expansion.
Operating profit ranking
Medipal reported higher operating profit, although both companies posted declines from a year earlier. Costs and shifts in demand weighed on earnings alongside the difference in sales scale.
Operating margin ranking
Ship Healthcare's operating margin exceeded Medipal's, while the two-company average remained around the mid-1% range. The ability to protect thin margins, not just grow sales, is key to competitiveness.
Winner and loser
Ship Healthcare led on growth momentum. Its sales rose 8.0% year on year, outpacing Medipal's 4.7% increase. Ship Healthcare also posted a 1.6% operating margin, above Medipal's 1.4%.
Medipal faced the greatest challenges. Its sales of ¥989.5 billion far exceeded Ship Healthcare's ¥176.4 billion, but its gross profit margin fell to 6.64% from 6.84% a year earlier. Selling, general and administrative expenses in areas including cosmetics and daily necessities increased 3.4% year on year, and operating profit declined 4.7%.
Ship Healthcare also had work to do on earnings, with operating profit down 5.7%. Even so, it outperformed Medipal in both sales growth and operating margin. Ship Healthcare led in growth and profitability, while Medipal faces pressure to turn its scale into profit.
Winner
Ship Healthcare
Laggard
Medipal
Strategic moves to watch
Ship Healthcare lifted sales 8.0% year on year through expanded SPD contracts with medical institutions and new consolidation from M&A. Operating profit fell 5.7%, in part because demand for equipment upgrades eased, but business expansion supported revenue growth. The company kept its full-year forecast unchanged.
Medipal recorded sales growth across all business segments, lifting revenue 4.7% year on year. But costs, particularly in cosmetics and daily necessities, weighed on earnings, and operating profit fell 4.7%. Gains of ¥6.061 billion from the sale of investment securities boosted net profit, but are distinct from recurring operating income.
Full-year operating profit forecasts are ¥53.5 billion for Medipal and ¥26.0 billion for Ship Healthcare. First-quarter operating profit was ¥13.4 billion and ¥2.8 billion, respectively. Meeting the plans will depend not only on simple progress rates but also on a recovery in demand and cost controls in the second half.
Risks shared across the industry
- Thin margins and rising costs. Operating margins were 1.6% at Ship Healthcare and 1.4% at Medipal. Continued increases in logistics and labor costs could put further pressure on profitability.
- Changes to medical systems and reimbursement. A revision to dispensing fees weighed on Ship Healthcare's earnings. Policy changes can also affect the investment capacity of client medical institutions and pharmacies.
- Demand swings and project timing. At Ship Healthcare, a lull in equipment upgrade demand contributed to the operating profit decline. Reliance on large projects and upgrade schedules can make quarterly results more volatile.
- Balancing price competition with profits. Medipal's gross profit margin declined. Even when sales volumes rise, price competition and changes in purchasing terms can leave less profit behind.
- Reliance on one-off gains. Medipal's net profit rose sharply with support from securities-sale gains. Investors will want to track a recovery in operating profit, not just net income.
For job seekers and career changers
Pharmaceutical and medical distribution is a sector that combines the stability of supporting healthcare with the challenge of finding ways to generate profit. Ship Healthcare stands out for expanding through SPD and M&A. Those interested in coordinating with medical institutions or improving their operations may want to look closely at its business.
Medipal has a larger sales base and a broad range of businesses, but improving profitability remains a challenge. When choosing an employer, candidates should look beyond company size to consider the growth prospects of the business they would join and the company's efforts to improve costs.
Year-on-year sales growth
Ship Healthcare's sales growth outpaced Medipal's, supported by expanded SPD contracts and M&A. Medipal also grew sales across all business segments, so both companies expanded revenue.
Year-on-year net profit growth
Medipal led by a wide margin in net profit growth, but the increase was boosted by gains from securities sales. Investors will need to assess the core business recovery alongside the decline in operating profit.